Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
Germline and tumor genetic testing of DNA repair genes in men with advanced prostate is increasingly recommended by U.S. and international guidelines as part of standard of care. Damaging mutations in homologous DNA repair pathways genes including BRCA2, BRCA1, PALB2, and ATM, and mismatch DNA repair genes including MSH2 and MSH6 have emerging clinical utility for risk assessment and treatment decision-making. This article summarizes a presentation at the 2019 Philadelphia Consensus Conference focused on the latest data at the intersection of germline and tumor genetic testing for prostate cancer patients.